News of Note—GeoVax, mumps outbreak and more

In this week's news of note, GeoVax published preclinical Zika vaccine results.

Here is some other vaccine news of note for this week.

> GeoVax published preclinical results showing that its Zika vaccine protected all mice in a lethal challenge. Release

> A mumps outbreak at Syracuse has climbed to 76 probable cases. Syracuse.com story

> Dynavax's FDA action date for Heplisav-B is coming up at the end of this week. Release

Read more on

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.